Kornimate/medical-research-clean huggingface dataset:
distress in rheumatoid arthritis patients

Conditions: Arthritis, Rheumatoid; Distress, Emotional

Summary: the goal of this observational study is to determine the frequency of psychological distress caused by the rheumatoid arthritis disease in patients with rheumatoid arthritis and to determine the factors associated with the distress. a routine rheumatoid arthritis patient examination (number of swollen and tender joints, disease activity, functional status, etc.) will be performed by the doctor to evaluate the patients. patients will be asked to fill out the questionnaires to evaluate their functional status and distress levels. demographic data such as age, gender, body mass index and disease duration will be recorded during routine follow-up of the patients. the duration of morning stiffness, the number of swollen and tender joints, disease activity and functional status will be evaluated by the doctor. disease activity will be evaluated with the das 28 score and functional status will be evaluated with the health assessment questionnaire. rheumatoid arthritis distress scale (rads) will be used to evaluate the distress due to rheumatoid arthritis.patients will be asked to fill out the questionnaires to evaluate their functional status and distress levels.

demographic data such as age, gender, body mass index and disease duration will be recorded during routine follow-up of the patients. the duration of morning stiffness, the number of swollen and tender joints, disease activity and functional status will be evaluated by the doctor. disease activity will be evaluated with the das 28 score and functional status will be evaluated with the health assessment questionnaire. rheumatoid arthritis distress scale (rads) will be used to evaluate the distress due to rheumatoid arthritis. das28 score is a score calculated by a mathematical formula based on the patient's swollen and tender joint counts, erythrocyte sedimentation rate and the patient's global assessment of disease activity. the health assessment questionnaire consists of twenty items and evaluates the degree of difficulty patients have in performing daily living activities. the total score varies between 0 and 3, with a higher score indicating a more serious impact on daily functional status. rheumatoid arthritis distress scale (rads) is a scale developed to evaluate the psychological distress experienced in patients with rheumatoid arthritis due to the effects of the disease. the total score varies between 0 and 5, with a higher score indicating more impact.

Eligibility criteria:
inclusion criteria: 1. having rheumatoid arthritis over the age of 18 2. having the cognitive state to understand what you read and answer questions exclusion criteria: 1. being currently receiving treatment for known psychological disorders such as depression and anxiety. 2. having another chronic disease that may cause psychological distress

Keywords: rheumatoid arthritis, distress
rituximab and abatacept effectiveness in differential treatment of interstitial lymphocytic lung disease in children with primary immunodeficiencies.

Conditions: Interstitial Lymphocytic Lung Disease

Summary: the rationale for this retrospective study is to evaluate the efficacy and safety of abatacept and rituximab treatment of illd in a cohort of pediatric patients with different forms of pid, who received one of the two therapy regimens predominantly based on the lesions histopathology.

primary immunodeficiencies (pid) represent a heterogeneous group of more than 400 inherited conditions with associated immune dysfunctions. though severe recurrent/chronic infections are the main cause of mortality and morbidity in pid, immune dysregulation manifesting with oncological and autoimmune or autoinflammatory conditions involving various organs and systems have been the focus of research in the recent years. the interstitial lymphocytic lung disease (illd) is one of the recently characterized non-malignant pid complications. immune dysregulation in illd causes reactive bronchi-associated lymphoid tissue (balt) hyperplasia that manifests in several pathomorphological forms: follicular bronchiolitis (fb), nodular lymphoid hyperplasia (nlh), and lymphocytic interstitial pneumonia (lip). treatment of illd patients with various immunosuppressive drugs leads to inconsistent results ranging from partial\\transient effect to no effect at all and has been often associated with adverse effects and an increase in infections' rate. therefore there is a need for targeted therapy of illd. in small cohorts of adult pid patients rituximab in combination with azathioprine proved to be effective. yet, the reports are scarce and there is currently no consensus on illd treatment, especially in children. the study will collect and analyze information on the effectiveness and safety of illd monotherapy with rituximab or abatacept, chosen predominantly based on the pathomorphological characteristics of lymphoid infiltration, as well as genetic defects, in a cohort of pediatric patients with pid.

Eligibility criteria:
inclusion criteria: 1. histological and/or radiological diagnosis of illd. 2. treatment with rituximab or abatacept for at least 12 months. 3. no signs of ongoing infectious pulmonary process at the start of the treatment. 4. regular ig substitution with trough igg levels \> 5g/l. exclusion criteria are nonadherence to therapy.

Keywords: interstitial lymphocytic lung disease primary immunodeficiency children treatment rituximab abatacept
pregnancy and neonatal follow-up of ongoing pregnancies established in clinical trial 38833 (p05783)

Conditions: Pregnancy; Neonates

Summary: the objective of this trial is to evaluate whether corifollitropin alfa (mk-8962, org 36286) treatment for the induction of multifollicular growth in women undergoing controlled ovarian stimulation (cos) prior to in vitro fertilization (ivf) or intracytoplasmic sperm injection (icsi) is safe for pregnant participants and their offspring.

this is a follow-up protocol to prospectively monitor pregnancy, delivery, and neonatal outcomes of all women who were treated with corifollitropin alfa and became pregnant during the base trial 38833. for this follow-up trial (38834), no investigational products will be administered and no study specific assessments are required, but information will be obtained as per standard clinical practice.

Eligibility criteria:
inclusion criteria: * participants who received one dose of corifollitropin alfa in trial 38833; * ongoing pregnancy confirmed by ultrasound at least 10 weeks after embryo transfer in trial 38833; * able and willing to give written informed consent. exclusion criteria: * none

Keywords: neonatal outcome congenital malformations in-vitro fertilization controlled ovarian stimulation follow-up
investigating efficacy and safety of biphasic insulin aspart 50 twice daily versus biphasic human insulin 50 twice daily both in combination with metformin in chinese subjects with type 2 diabetes mellitus

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in asia. the aim of the trial is to investigate the efficacy and safety of biphasic insulin aspart 50 (biasp 50) twice daily versus biphasic human insulin 50 (bhi 50) twice daily, both in combination with metformin, in chinese subjects with type 2 diabetes mellitus.


Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus (diagnosed clinically) for at least 12 months * currently treated with premixed human insulin 50 bid for at least 3 months prior to screening visit (visit 1) * currently treated with unchanged total daily dose of at least 1500 mg metformin or maximum tolerated dose at least 1000 mg/day metformin for at least 2 months prior to screening visit * glycosylated haemoglobin (hba1c) 7.0% and 9.0% (both inclusive) (central laboratory) exclusion criteria: * treatment with any insulin secretagogue, alfa-glucosidase inhibitors, thiazolidinedione (tzd), dipeptidyl peptidase-4 (dpp-4) inhibitors and glucagon-like peptide-1 (glp-1) receptor agonists within the last 3 months prior to screening * previous use of any insulin other than premixed human insulin 50 bid within 3 months prior to visit 1 * previous use of insulin intensification treatment (premixed insulin thrice daily, basal bolus regimen, and continuous subcutaneous insulin infusion (csii)) for more than 14 days
evaluation of efficacy of house dust mite immunotherapy in children with bronchial asthma

Conditions: Asthma

Summary: the aim of the study is to assess the effect of specific immunotherapy (sit) to dust mites on clinical symptoms, reliever drugs usage, inhaled glucocorticosteroid usage, quality of life, lung function, bronchial hyperreactivity with methacholine, and presence and type of allergy after three years of sit in children with asthma.

according to global initiative for asthma treatment of asthma is based on avoidance of allergens, pharmacological treatment, and specific immunotherapy. the aim of the study is to assess the effect of specific immunotherapy (sit) to dust mites on clinical symptoms, reliever drugs usage, inhaled glucocorticosteroid usage, quality of life, lung function, bronchial hyperreactivity with methacholine, and presence and type of allergy after three years of sit in children with asthma.

Eligibility criteria:
inclusion criteria: * patients allergic to house dust mites * patients with moderate bronchial asthma * patients with controlled asthma * patients who were qualified for immunotherapy and gave written informed consent for immunotherapy (active treatment group) * patients who were qualified for immunotherapy and did not agree with this kind of treatment - did not give written informed consent for immunotherapy (control group) exclusion criteria: * patients allergic for other perennial and seasonal allergens * patients with other chronic diseases that either put the patient at risk when participating in the study or could influence the results of the study or the patient's ability to participate in the study as judged by the investigator * medications that resulted in patient exclusion included:anti-parasites or oral corticosteroids within 6 months before the first visit.

Keywords: asthma immunotherapy efficacy children symptoms score quality of life spirometry pc20m
clinical evaluation of leech therapy in the treatment of knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: this study has been designed to conduct as randomized comparative clinical study.

two groups, group b received qurse mafasil tablet orally two tablets two times daily for 8 weeks while group a received leech therapy once weekly for 8 weeks along with qurse mafasil.

Eligibility criteria:
inclusion criteria: * knee osteoarthritis exclusion criteria: * pregnancy, * lactation, * anaemia

Keywords: qurse mafasil leech therapy hirudinaria granulosa
evaluation of agreement between ct scan and 3d-dxa measurements on the lombar spine

Conditions: Bone Fracture

Summary: dual-energy x-ray absorptiometry is frequently used to measure bone mineral density. a new medical device, box 3d dxa, creates a 3d image using a statistics reconstruction model developed on the femur. this new imaging technique does not require additional irradiation and ought to improve bone measures as well as incorporating densitometric parameters into the diagnosis. this study will test the reconstruction of the 3d image from lombar spine measurements and compare accuracy against measurements made using ct scan.


Eligibility criteria:
inclusion criteria: * the patient must have given their free and informed consent and signed the consent form * the patient must be a member or beneficiary of a health insurance plan * the patient is at least 18 years old * the patient has been referred by a doctor for a pet/ct (positron emission tomography-computed tomography) scan or a spect (single photon emission computed tomography) scan in the nuclear medicine and medical biophysics department of nimes hospital or a bone scan including a spect/ct (single photon emission computed tomography coupled with a ct scan) exclusion criteria: * the subject is participating in an interventional study, or is in a period of exclusion determined by a previous study * the subject refuses to sign the consent * it is impossible to give the subject informed information * the patients is under judicial protection or state guardianship * the patient is pregnant or breast feeding * the subject has a observably serious scoliosis * subject has previously had spinal or hip surgery * subject weighs more than 200kg and/or is more than 2 meters tall by 5+65cm wide and 70cm diameter * patient uses an insulin pump or wears an insulin or morphine tubing or any attenuating equipment affecting the hips or lumbar spine * subject has already had an x-ray exam using a contrast product such as barium in the 7 days preceding the visit * subject having undergone γ radiation exam in the 15 days preceding the visit
evaluating the role of igf-1 and s-klotho in plaque phenotype and vulnerability: the vision study.

Conditions: Ischemic Heart Disease; Chronic Coronary Syndrome; Optical Coherence Tomography (OCT)

Summary: insulin-like growth factor 1 (igf-1) is the primary peripheral mediator of growth hormone (gh) and has pleiotropic effects on development, differentiation, metabolism, and cell survival. several in vivo and in vitro studies suggest that igf-1 may have a protective effect on atherosclerosis as it suppresses macrophage recruitment and activation, cytokine production, and extracellular matrix degradation while promoting smooth muscle cell migration and proliferation and extracellular matrix deposition. the protein sklotho appears to be closely related to the gh-igf-1 axis, and some animal and in vitro studies hypothesize its protective role in the cardiovascular system. the gh-igf-1 axis and sklotho influence mechanisms determining coronary atherosclerosis. circulating levels of igf-1 and sklotho may correlate with the morphology of atherosclerotic plaques and particularly with the vulnerability of coronary lesions. objectives: to evaluate the correlation between atherosclerotic plaque phenotype and the gh-igf-1 axis and sklotho in patients with chronic coronary syndrome using intravascular imaging with optical coherence tomography (oct). methods:all patients with chronic coronary syndrome who meet the inclusion and exclusion criteria and undergo coronary angiography and intravascular imaging with optical coherence tomography will be included. at the end of the procedure, a blood sample will be taken to measure igf-1, sklotho, and gh receptor (ghr) polymorphism.


Eligibility criteria:
inclusion criteria: * patients with chronic coronary syndrome undergoing coronary angiographic study. * patients undergoing intravascular imaging with oct during coronary angiographic study at the operator's discretion, for diagnostic purposes and/or to guide possible coronary artery disease treatment. * patients with at least 18 years of age. * patients able to provide informed consent. exclusion criteria: * pregnancy. * pathological excess or deficiency of igf-1. * stage iv chronic renal failure. * severe liver disease. * cachexia and/or malnutrition states. * bmi \<18.5. * hba1c ≥ 8.5%. * left ventricle ejection fraction (lvef) \<= 35% * patients with aorto-coronary bypass. * oct analysis conducted on vessels with previous percutaneous coronary intervention with stent implantation.
phase ii gemcitabine + cisplatin +/- iressa bladder cct

Conditions: Bladder Cancer

Summary: the primary objective of the study is to assess the activity of zd1839 250 mg once daily in addition to the standard chemotherapy in patients with advanced or metastatic transitional cell carcinoma of the urothelium by estimating the time to progression.


Eligibility criteria:
inclusion criteria: * histologically or cytologically-confirmed transitional cell carcinoma of the urothelium * locally advanced or metastatic disease * at least one measurable lesion as defined by recist * chemotherapy-naiv exclusion criteria: * previous chemotherapy or other systemic antitumour therapy * other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma, cervical cancer in situ or locally limited prostate cancer

Keywords: bladder cancer transitionel cell cancer of the urothelium
an open-label, long-term study of telmisartan plus amlodipine fixed-dose combination

Conditions: Hypertension

Summary: to assess the long term safety and efficacy of telmisartan plus amlodipine fdc in patients with essential hypertension who failed to control their bp with either monotherapy


Eligibility criteria:
inclusion criteria: 1. patients with essential hypertension 2. outpatient exclusion criteria: * patients whose sbp \>=180 mmhg or dbp \>=110 mmhg at the end of treatment visit of the double-blind treatment period in the "non-responder trials" * patients who have met any of the exclusion criteria defined in the "non-responder trials"
a modernized approach to prenatal care in low risk women

Conditions: Pre-eclampsia; Intrauterine Growth Retardation

Summary: the investigators plan to identify 80 pregnant women at low risk for obstetrical complications and replace 4-5 routine third trimester visits with a structured program of home weight, blood pressure and urine protein monitoring along with regular structured phone interviews and a 28 week ultrasound. the investigators hypothesis is that this protocol is both safe and acceptable.


Eligibility criteria:
inclusion criteria: * age \< 35 * doesn't live alone * current phone number * previous pregnancy * no prior second trimester miscarriage/fetal loss after 13 weeks * previous delivery * if yes, all had uncomplicated antepartum course * all deliveries \> 37 weeks * all birth weight \> 2700 grams * maternal bmi between 18.5 and 30 * no chronic medical problems * no current substance abuse * spontaneous conception * no family history of pre-eclampsia * agrees to first trimester aneuploidy screening exclusion criteria: * clinically significant abnormalities on routine physical exam or routine laboratory results * multiple pregnancy * fetal abnormalities detected on either the 11-14 week or the 18 week ultrasound including a nuchal translucency \> 3 mm but not including second trimester markers for aneuploidy or a low lying placenta * a risk of fetal aneuploidy on first trimester screening \> 1:300 papp-a \< 5 %ile or hcg \< 1 %ile (abnormalities of these serum analytes routinely obtained as part of aneuploidy screening are associated with an increased risk of adverse outcome) * elevated blood pressure (\> 140/90), * cervical length \< 3 cm at the 18 week ultrasound (which is associated with an increased risk for preterm delivery).
exploring the experience of communication for patients with depression

Conditions: Depression

Summary: according to the statistics released by the department of health,executive yuan in 2005,depression, cancer and aids will become the three main diseases of the 21st century.the prevalence of depression is 5.8% for males and 9.5% for women in the worldwide total population each year.depression ranks second next to cardiovascular disease and impacts on social and economic burdens.from the perspectives of prevalence,suicide rate,loss of workforce,family burden,co-morbidities and health care expenses,the issues related to caring for patients with depression should not be overlooked.communication is often neglected while exploring the issues of caring for depressed patients,which can consequently affect their family,work performance,social interaction,and even leads to a risk of suicide.therefore,in order to enhance their psychological adjustment and health management,it is particularly important to achieve effective communications.

this study aims to investigate the experiences of communication for patients with depression.purposive sampling will be used to recruit participants in this study.eligible participants consist of those who attend the outpatient department of psychiatry regularly,have emotional stability and clear consciousness,more than 20 years old,can be communicated in mandarin or taiwanese,and are willing to take the interviews.in-depth interviews will be conducted to collect qualitative data,and data will be categorized and analyzed according to tesch(1990).sampling will be stopped until data saturation.the findings may be referenced by the relevant agencies and medical institutions to care the patients with depression,as well as provide a basis for nursing care and education.

Eligibility criteria:
inclusion criteria: * psychiatric physician-diagnosed patients with major depression,including major depressive disorder,identified patients with stable and stable condition treatment by a physician. * able to communicate to the language of the country or taiwan. * by explanations can share experiences,and has executed a written consent to. exclusion criteria: * combined with other mental illness. * depression in patients with unstable condition,including serious and has a tendency to suicide,violence and attacks.

Keywords: depression experiences of communication
folic acid supplementation in eating disorder

Conditions: Eating Disorders

Summary: the aim of this study was to determine the effect of folic acid supplementation on homocysteine levels in a group of patients with eating disorders (ed) with low folate intake. the secondary aims were to evaluate the evolution on cognitive and depressive status after the intervention.

some authors have identified the presence of increased levels of homocysteine in patients with eating disorders and attempts have been made to find some association between this and the high rates of depression and cognitive function impairment recorded in these patients. it is still not known what causes this increase in homocysteine levels, whether the levels return to normal after the nutritional state is normalised and what strategies must be employed to carry out this normalisation.

Eligibility criteria:
inclusion criteria: * males and females diagnosed with eating disorders (dsm-iv criteria of the american psychiatric association, 2000) * age \> 18 years * low folate intake based on the recommended daily intake in terms of age (institute of medicine, 1998) exclusion criteria: * patients with contraindications for folic acid supplementation due to hypersensitivity to folic acid or anaemia due to lack of b12 * patients who routinely used drugs that interfere with folic acid absorption (analgesics, anticonvulsants, hydantoin, carbamazepine, antacids, antibiotics, cholestyramine, methotrexate, pyrimethamine, triamterene, trimethoprim and sulphonamides) * patients with vitamin and mineral supplements intake.

Keywords: folate homocysteine cognitive function eating disorders depression.
cardio-ttransform magnetic resonance imaging (mri) sub-study

Conditions: Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Summary: the main purpose of this study is to measure the amyloid burden, defined as extracellular volume (ecv) assessed by magnetic resonance imaging (mri) over time in a subset of up to 150 participants enrolled in ion-682884-cs2 (nct04136171).

this pilot study will determine the efficacy of ion-682284 in reducing the amyloid deposit on the heart tissue compared to placebo.

Eligibility criteria:
inclusion criteria: to participate in the ion-682884-cs2mri sub-study, participants must meet all inclusion criteria of the study protocol ion-682884-cs2 (nct04136171). exclusion criteria 1. contraindication or sensitivity to mri contrast agents 2. orthopnea of sufficient severity to preclude supine scanning at screening. 3. weight or body girth exceeds the limits of the cardiac mri machine specifications. 4. contraindication to cardiac mri scanning, as assessed by local mri safety questionnaire/checklist.

Keywords: ttr amyloidosis cardiomyopathy